Kiora Pharmaceuticals, Inc. (KPRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.1820 |
| Open | 0.1992 |
| Bid | 0.1615 x 3100 |
| Ask | 0.1625 x 1200 |
| Day's Range | 0.1600 - 0.2031 |
| 52 Week Range | 0.1400 - 2.3400 |
| Volume | |
| Avg. Volume | 2,071,741 |
| Market Cap | 5.974M |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7740 |
| Earnings Date | Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for KPRX
Related Research
- Kiora Pharmaceuticals, Inc.Analyst Report: Bausch Health Companies Inc.Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.RatingFair ValueEconomic Moat4 days agoMorningstar
- Newsfile
Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Salt Lake City, Utah--(Newsfile Corp. - August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022."In the first half, we continued to advance three core programs toward their next phase of clinical development," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "With the recent financing, we are now in a position to ...
- Newsfile
Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Salt Lake City, Utah--(Newsfile Corp. - July 28, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has been granted a U.S. patent covering hydrogel-based sustained release platforms, inclusive of KIO-201, which enable controlled release of antibiotics for the treatment of ocular diseases. The intellectual property, US Patent No. 11,376,214, relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and have poten
- Newsfile
Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Salt Lake City, Utah--(Newsfile Corp. - July 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses.The offering was comprised of (i) 23,695,697 shares of common s
